BDP9066

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

BDP9066 是肌强直性肌营养不良相关 Cdc-42 结合激酶 MRCK 的选择性有效抑制剂，其在 SCC12 细胞中测得对 MRCKβ 的IC50 值为 64 nM，对 MRCKα/β 的 Ki 值分别为 0.0136 nM 和 0.0233 nM。BDP9066 可用来研究皮肤癌。

BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.

BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion.

BDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes.

——

Cell Cycle/DNA Damage

ROCK

ROCK

——

——

2226507-04-4

348.44

C20H24N6

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 10 mg/mL (28.70 mM; 超声助溶 )

C1CC[C@@]2(CCCN(C2)c2cc[nH]c3ncc(-c4ccncn4)c23)NC1

——

(-20℃)

With Ice Pack

≥ 2 years